{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:36:30Z","timestamp":1789436190414,"version":"build-2803163510"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alopecia is associated with erenumab post-marketing, but no cases have been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe two patients that reported temporary hair loss and review the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The first patient experienced alopecia within three months of starting erenumab, which did not improve with ongoing use or transition to fremanezumab. The second patient reported alopecia within two weeks of starting erenumab, which continued after transition to galcanezumab; months later, there was also recurrent hair loss within one month of starting fremanzeumab. According to FAERS (last accessed 18 August 2022), alopecia was reported most with erenumab (1158), followed by galcanezumab (554), fremanezumab (175), eptinezumab (23), rimegepant (26), ubrogepant (4), and atogepant (3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most events were reported in women and non-serious. The potential mechanism of alopecia with drugs targeting calcitonin gene-related peptide or its receptor possibly includes disruptions in the microvascular circulation and other homeostatic mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024221143538","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:22:56Z","timestamp":1675567376000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review"],"prefix":"10.1177","volume":"43","author":[{"given":"Miguel","family":"Ruiz","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Florida International University, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cocores","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Headache, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J","family":"Goadsby","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology, And Neuroscience, King\u2019s College, London, UK"},{"name":"Department of Neurology, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-252X","authenticated-orcid":false,"given":"Teshamae S","family":"Monteith","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Headache, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"bibr1-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.06.003"},{"key":"bibr2-03331024221143538","unstructured":"US Food & Drug Administration. Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf (2018, accessed 15 October 2022)."},{"key":"bibr3-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"bibr4-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"bibr5-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr6-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00469-8"},{"key":"bibr7-03331024221143538","unstructured":"US Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (2021, accessed 18 August 2022)."},{"key":"bibr8-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2007.04.009"},{"key":"bibr9-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2012.08.002"},{"key":"bibr10-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2725"},{"key":"bibr11-03331024221143538","unstructured":"UK Government. The Yellow Card Scheme: guidance for healthcare professionals, https:\/\/www.gov.uk\/guidance\/the-yellow-card-scheme-guidance-for-healthcare-professionals (2022, accessed 07 November 2022)."},{"key":"bibr12-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01432.x"},{"key":"bibr13-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199703240-00015"},{"key":"bibr14-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2012.04.006"},{"key":"bibr15-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01227-5"},{"key":"bibr16-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"bibr17-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"bibr18-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"bibr19-03331024221143538","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221143538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024221143538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221143538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:32Z","timestamp":1777387532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024221143538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/03331024221143538"],"URL":"https:\/\/doi.org\/10.1177\/03331024221143538","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"03331024221143538"}}